Future research in EGPA should be targeted at clarifying its pathophysiology and the therapies best suited to achieve optimal outcomes. The diagnostic landscape of eosinophilic granulomatosis with ...

Red blood cell antibody seroconversion in pregnancy was uncommon, with a rate of 0.26%. Clinically significant antibody seroconversion of red blood cells during pregnancy is rare, occurring in only ...

The study revealed that the 2022 criteria demonstrated high sensitivity and specificity for EGPA, low sensitivity and high specificity for GPA, and high sensitivity and low specificity for MPA, with ...

Thirty-four proteins—some not typically associated with eosinophilic inflammation—were affected by mepolizumab treatment but not by glucocorticoids. A recent study published in Allergy suggests that ...

Because acute chest syndrome in SCD can be life-threatening, it is important for physicians to recognize this disorder and initiate treatment accordingly. Acute chest syndrome (ACS) is one of the most ...

(Getty Images) The SPPB is a validated tool to predict morbidity and mortality, often among older adults. After adjusting for covariates, each 1-point increase in SPPB score was associated with a 13% ...

Current protocols often use RhD-positive blood, which can increase the risk of alloimmunization in females without the RhD factor. This immune response can complicate future pregnancies and lead to ...

HDFN remains a substantial health challenge globally, especially in areas where antenatal care is lacking. Hemolytic disease of the fetus and newborn (HDFN) remains a significant public health ...

Man with hand on his chest, seeing doctor Over time, the number of new ATTR-CM diagnoses with no heart failure symptoms progressively increased. Symptomatic heart failure developed in 50% of patients ...

The varied manifestations of IgG4-RD can make the diagnosis challenging, but prompt treatment can resolve symptoms and prevent recurrence. A new case has been reported of a patient with immunoglobulin ...

Efgartigimod alfa and hyaluronidase-qvfc (Vyvgart Hytrulo ®) precision therapy has been approved by China’s National Medical Products Administration (NMPA) to treat chronic inflammatory demyelinating ...

In NMOSD, satralizumab is believed to be more effective in preventing relapse of optic neuritis than of myelitis. Satralizumab was safe and effective at preventing relapses of optic neuritis in ...